Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v9-EN Version v2-FR
Language English French
Date Updated 2024-06-18 2024-06-10
Drug Identification Number 02454343 02454343
Brand name PRAXBIND PRAXBIND
Common or Proper name Praxbind Praxbind
Company Name BOEHRINGER INGELHEIM (CANADA) LTD LTEE BOEHRINGER INGELHEIM (CANADA) LTD LTEE
Ingredients IDARUCIZUMAB IDARUCIZUMAB
Strength(s) 50MG 50MG
Dosage form(s) SOLUTION SOLUTION
Route of administration INTRAVENOUS INTRAVENOUS INTRAVENOUS INTRAVENOUS
Packaging sizes (GTIN) (See additional packaging sizes) (See additional packaging sizes)
Additional packaging sizes 2x50mL 2x50mL
ATC code V03AB V03AB
ATC description ALL OTHER THERAPEUTIC PRODUCTS ALL OTHER THERAPEUTIC PRODUCTS
Reason for shortage Demand increase for the drug. Demand increase for the drug.
Anticipated start date 2024-06-10 2024-06-10
Actual start date 2023-06-10 2023-06-10
Estimated end date 2024-06-18 2024-06-18
Actual end date 2024-06-17
Shortage status Resolved Actual shortage
Tier 3 Status No No
Company comments Expedited resupply received and released for sale Resupply expedited
Health Canada comments